Wednesday, November 18, 2026

Lotte Biologics Completes 120,000-Liter Songdo Production Hub; Commercial Production to Begin in 2027

Input
2026-11-18 09:16:11
Updated
2026-11-18 09:16:11
A view of Lotte Biologics' Songdo plant. Photo courtesy of Lotte Biologics.
[Financial News] Lotte Group has secured a domestic production base for its contract development and manufacturing organization (CDMO) business in biopharmaceuticals. With Lotte Biologics completing a 120,000-liter biopharmaceutical production plant in Songdo, Incheon, the company will work to build a global production system linked to its Syracuse plant in the United States. It plans to step up its push into the global CDMO market, starting commercial production in 2027.
Lotte Biologics held a completion ceremony for Plant 1 at its Songdo Bio Campus in Incheon on the morning of the 18th. Around 300 people attended, including Lotte Group Chairman Shin Dong-bin; Lotte Biologics co-CEOs James Park and Shin Yoo-yeol; government and local government officials; and lawmakers. Prime Minister Han Seong-suk congratulated the company on the completion in a video message.
Construction of Songdo Plant 1 began in March 2024. The plant has a gross floor area of about 99,558 square meters. It consists of a production building, a utilities building, an employee welfare building and a wastewater treatment plant, among other facilities, and has a total biopharmaceutical production capacity of 120,000 liters. After receiving approval for use in June, it completed GMP (Good Manufacturing Practice) preparations six months ahead of the original schedule.
The company is currently carrying out follow-up procedures for commercial production, including equipment qualification and validation. It plans to begin full-scale commercial production in 2027 after completing the related preparations.
With the completion of this plant, Lotte Biologics has secured a large-scale production facility in South Korea, following its facility in Syracuse, New York State. Its strategy is to respond to customers' production needs and demand for supply-chain diversification by linking its U.S. production hub with the Songdo plant. The Songdo plant is expected to serve as a key hub for large-scale commercial production.
In his congratulatory address that day, Chairman Shin Dong-bin presented the bio business as a future growth engine for Lotte Group. Shin said, “The bio business is a future growth engine for Lotte Group and a next-generation industry that will lead South Korea’s next generation.” He added, “I hope Songdo Bio Campus Plant 1 will be an important turning point that not only drives Lotte Group’s growth but also raises the competitiveness of South Korea’s bio industry to a new level.”
Lotte Biologics is pursuing a plan to expand production capacity by building a total of three plants at the Songdo Bio Campus. Following Plant 1's completion, the actual transition to commercial production and additional orders are expected to be crucial to expanding the business. That is because securing customers among global pharmaceutical companies and increasing plant utilization will be important to turning large-scale investment in facilities into revenue.
Co-CEO Shin Yoo-yeol stressed that the completion of the Songdo plant would provide a foundation for strengthening South Korea’s capacity for large-scale biopharmaceutical production. He said, “We will be a CDMO partner that works alongside our customers over the long term, with quality, technology and trust as our foundation.”
Co-CEO James Park said, “Songdo Plant 1 achieved GMP readiness six months ahead of the original schedule.” He added, “It will serve as a growth base for taking another step forward in the global market.”

[email protected] Jung Sang-hee Reporter